This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2004 Aug 3;171(3):229-30.

doi: 10.1503/cmaj.1040330.

New directions in drug approval

PMID: 15289416
PMCID: PMC490068
DOI: 10.1503/cmaj.1040330

New directions in drug approval

Joel Lexchin. CMAJ. 2004.

. 2004 Aug 3;171(3):229-30.

doi: 10.1503/cmaj.1040330.

Author

PMID: 15289416
PMCID: PMC490068
DOI: 10.1503/cmaj.1040330

No abstract available

PubMed Disclaimer

Figures

Figure
Photo by: Carole Lalonde

See this image and copyright information in PMC

Similar articles

The timeliness of new drug approvals in Canada.
Rawson NS. Rawson NS. Int J Health Serv. 1995;25(1):153-65; discussion 167-71. doi: 10.2190/3XHM-EW8F-5HJY-2D5N. Int J Health Serv. 1995. PMID: 7794387
Canadian and US drug approval times and safety considerations.
Rawson NS, Kaitin KI. Rawson NS, et al. Ann Pharmacother. 2003 Oct;37(10):1403-8. doi: 10.1345/aph.1D110. Ann Pharmacother. 2003. PMID: 14519031
Drug approval system questioned in US and Canada.
Eggertson L. Eggertson L. CMAJ. 2005 Feb 1;172(3):317-8. doi: 10.1503/cmaj.045312. CMAJ. 2005. PMID: 15684107 Free PMC article. No abstract available.
The DINs and don'ts of herbal/natural preparations.
Mishkin S. Mishkin S. Can J Gastroenterol. 1999 May;13(4):335-7. Can J Gastroenterol. 1999. PMID: 10360994 Review. No abstract available.
New drug approval process in Japan.
Hayakawa T. Hayakawa T. Curr Opin Biotechnol. 1999 Jun;10(3):307-11. doi: 10.1016/S0958-1669(99)80055-X. Curr Opin Biotechnol. 1999. PMID: 10361082 Review. No abstract available.

See all similar articles

Cited by

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
Lexchin J. Lexchin J. CMAJ. 2005 Mar 15;172(6):765-7. doi: 10.1503/cmaj.045021. CMAJ. 2005. PMID: 15767610 Free PMC article. No abstract available.

References

1. Government of Canada. The Canada we want: Speech from the Throne to open the Second Session of the Thirty-Seventh Parliament of Canada. Available: www.sft-ddt.gc.ca/vnav/07_e.htm. (accessed 2004 Jul 6).
1. Department of Finance, Canada. Building the Canada we want. Budget 2003: investing in Canada's health care system [cat no F1-23/2003-4E]. Ottawa: The Department; 2003. Available: www.fin.gc.ca/budget03/booklets/bkheae.htm (accessed 2004 Jul 6).
1. Health Canada. Improving Canada's regulatory process for therapeutic products: building the action plan. Public Policy Forum multi-stakeholder consultation; 2003 Nov 2-3. Available: www.ppforum.ca/ow/ow_e_05_2003/Presentation%20_Overview_of_Action_Plan.pdf (accessed 2004 Jul 6).
1. Rawson NSB. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made? Clin Ther 2003;25:1230-47. - PubMed
1. Patented Medicine Prices Review Board. Annual report 2001. Ottawa: The Board; 2002.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources